$1.43
-0.03 (-2.05%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where DRMA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 1 tracked-famous manager (SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| DMT310-009 Topical in the Treatment of Acne VulgarisNCT06090721Efficacy as measured by lesion countsRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: DMT310, Placebo | Acne Vulgaris | 520 | 2025-03-31actual | 2025-08-22 |
| DMT310-005 Topical in the Treatment of Acne RosaceaNCT05108025Efficacy as measured by lesion countsRandomized · Quadruple-masked · Treatment | Phase 2 | Unknown status | Drug: Topical Powder, Placebo Topical Powder | Acne Rosacea | 180 | Dec 2022 | 2022-12-08 |
| DMT310-003 Topical in the Treatment of Acne VulgarisNCT04106778Efficacy as measured by lesion countsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: DMT310, Placebo | Acne Vulgaris | 181 | 2020-05-04actual | 2020-07-22 |
| DMT310-001 Topical in the Treatment of Acne VulgarisNCT03536637Efficacy as measured by lesion countsRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: DMT310, Hydrogen Peroxide, Placebo | Acne Vulgaris | 121 | 2018-12-30actual | 2020-07-22 |
| DMT210 Topical Gel in the Treatment of Acne RosaceaNCT03003104Efficacy as measured by Inflammatory lesion countsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: DMT210 Topical Gel 5% · Other: Vehicle Control | Acne Rosacea | 107 | 2017-08-30actual | 2018-04-18 |
| DMT210 Topical Gel in the Treatment of Atopic DermatitisNCT02949960ADSI (Atopic Dermatitis Severity Index) score of each Target lesionRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: DMT210 Topical Gel, Vehicle Control | Atopic Dermatitis | 19 | 2017-07-14actual | 2018-04-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19